Concepedia

Author

Jorge Romaguera

The University of Texas MD Anderson Cancer CenterORCID

Also Known As

J E Romaguera, J ROMAGUERA, J Romaguera, J. E. Romaguera, J. Romaguera, J.E Romaguera, J.E. Romaguera, JORGE ROMAGUERA, Jorge E Romaguera, Jorge E. Romaguera

416

Publications

18.5K

Citations

68

H-Index

96

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterLymphoma Research Foundation
JR

About

Jorge Romaguera is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pathology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

36

70

4.7K

2

Health Sciences

15

17

1K

3

Cell Biology

7

7

368

4

Engineering

1

1

37

5

Blood Transplantation

1

1

117

Jorge Romaguera

×

195

Publications

16.9K

Citations

65

H-Index

YearCitations

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang, Simon Rule, Peter Martin,

New England Journal of Medicine

2013

1.7K

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Raoul Herbrecht, Jorge Romaguera, Gregor Verhoef,

Journal of Clinical Oncology

2009

639

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Jorge Romaguera, Luis Fayad, Maria Alma Rodriguez,

Journal of Clinical Oncology

2005

557

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin, Fuliang Chu, Min Zhang,

The Lancet Oncology

2013

528

Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

André Goy, Anas Younes, Peter McLaughlin,

Journal of Clinical Oncology

2004

526

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

William S. Velasquez, Peter McLaughlin, Fredrick B. Hagemeister,

Journal of Clinical Oncology

1994

427

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

Michael Wang, Kristie A. Blum, Peter Martin,

Blood

2015

396

Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience

Yasuhiro Oki, Mansoor Noorani, Pei Lin,

British Journal of Haematology

2014

361

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

Issa F. Khouri, Jorge Romaguera, Hagop M. Kantarjian,

Journal of Clinical Oncology

1998

358

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Michael Wang, Luis Fayad, Nicolaus A. Wagner‐Bartak,

The Lancet Oncology

2012

296

Page 1